Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Houston, TX
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Norfolk, VA
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Spokane, WA
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Camperdown,
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Camperdown,
Click here to add this to my saved trials
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy
Status: Enrolling
Updated:  12/31/1969
UNC Healthcare
mi
from
Chapel Hill, NC
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy
Status: Enrolling
Updated: 12/31/1969
UNC Healthcare
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy
Status: Enrolling
Updated:  12/31/1969
Rex Cancer Center
mi
from
Raleigh, NC
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy
Status: Enrolling
Updated: 12/31/1969
Rex Cancer Center
mi
from
Raleigh, NC
Click here to add this to my saved trials
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy
Status: Enrolling
Updated:  12/31/1969
Rex Cancer Center - Wakefield
mi
from
Raleigh, NC
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy
Status: Enrolling
Updated: 12/31/1969
Rex Cancer Center - Wakefield
mi
from
Raleigh, NC
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Phoenix, AZ
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Long Beach, CA
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Sacramento, CA
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Gainesville, FL
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Orlando, FL
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Tampa, FL
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Augusta, GA
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Augusta, GA
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Macon, GA
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Macon, GA
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Savannah, GA
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Oak Lawn, IL
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Detroit, MI
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Las Vegas, NV
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
New Brunswick, NJ
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Brooklyn, NY
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Charlotte, NC
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Cincinnati, OH
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Dayton, OH
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Oklahoma City, OK
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Portland, OR
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Charleston, SC
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Salt Lake City, UT
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Charlottesville, VA
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Algiers,
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Algiers,
Click here to add this to my saved trials
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Washington,
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene
Status: Enrolling
Updated:  12/31/1969
Methodist Hospital
mi
from
Houston, TX
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene
Status: Enrolling
Updated: 12/31/1969
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia
An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/31/1969
Brooklyn Urology Research Group
mi
from
Brooklyn, NY
Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia
An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/31/1969
Brooklyn Urology Research Group
mi
from
Brooklyn, NY
Click here to add this to my saved trials
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
A Phase I Study of 90Y-BC8-DOTA Monoclonal Antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
A Phase I Study of 90Y-BC8-DOTA Monoclonal Antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Minimizing Physical Function Decline in Older Adults Receiving Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Minimizing Physical Function Decline in Older Adults Receiving Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
A Phase II Study of Crenolanib Besylate in Subjects With Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
A Phase II Study of Crenolanib Besylate in Subjects With Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
A Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematolymphoid Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Stanford, CA
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
A Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematolymphoid Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
Treatment of Steroid Non-responsive Acute GVHD With Alpha 1 Antitrypsin (AAT). A Phase I/II Study
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
Treatment of Steroid Non-responsive Acute GVHD With Alpha 1 Antitrypsin (AAT). A Phase I/II Study
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma
A Prospective, Randomized Comparison Of Rapid Thrombelastography (r-TEG) And Conventional Coagulation Testing For Guiding The Diagnosis And Haemostatic Resuscitation Of Trauma Patients At Risk For Post-Injury Coagulopathy
Status: Enrolling
Updated:  12/31/1969
Denver Health Medical Center
mi
from
Denver, CO
Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma
A Prospective, Randomized Comparison Of Rapid Thrombelastography (r-TEG) And Conventional Coagulation Testing For Guiding The Diagnosis And Haemostatic Resuscitation Of Trauma Patients At Risk For Post-Injury Coagulopathy
Status: Enrolling
Updated: 12/31/1969
Denver Health Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated:  12/31/1969
UC San Diego Moores Cancer Center - Investigational Drug Services
mi
from
La Jolla, CA
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated: 12/31/1969
UC San Diego Moores Cancer Center - Investigational Drug Services
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated:  12/31/1969
UC San Diego Medical Center - La Jolla
mi
from
La Jolla, CA
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated: 12/31/1969
UC San Diego Medical Center - La Jolla
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated:  12/31/1969
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated: 12/31/1969
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated:  12/31/1969
Keck Hospital of USC
mi
from
Los Angeles, CA
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Status: Enrolling
Updated: 12/31/1969
Keck Hospital of USC
mi
from
Los Angeles, CA
Click here to add this to my saved trials